Forward this message to a colleague.
Wednesday, March 18, 2015  |  Volume 7 / Number 6  |  A Production of the BioProcessing Journal
Career Development
Job Opportunities
Laramie, Wyoming USA
4th International Symposium on Higher Order Structure of Protein Therapeutics
April 13–15, 2015
Boston, Massachusetts USA
Immunopharmacology - Vaccipharma 2015
June 14–19, 2015
Varadero Beach, Cuba
PREP 2015—28th International Symposium on Preparative and Process Chromatography
July 26–29, 2015
Philadelphia, Pennsylvania USA
Techno-Blast Masthead
An artist’s rendering of the retrovirus.

Email your cell images to the editor today!
Suggested Reading
Biopharmaceutical Manufacturing: Historical and Future Trends in
Titers, Yields, and Efficiency in Commercial-Scale Bioprocessing
By Ronald A. Rader and Eric S. Langer, BioPlan Associates Inc.
Products & Services
New Bioreactor Systems Enhanced with Software for Design of Experiments (DoE)


For more information,
please visit sartorius.com.
Sartorius Stedim Biotech's (SSB) 2015 version of the ambr® systems (ambr® 15 and ambr® 250) will be supplied with integrated BioPAT® MODDE Software for Design of Experiments (DoE), powered by Umetrics. The integrated DoE software will enable scientists to quickly establish a Design Space where relevant bioprocessing conditions are varied simultaneously. Users can rapidly configure DoE experiments via work packets that are exported from the software to the ambr system; configuring each micro bioreactor with its own DoE defined bioprocessing parameters.

The data generated from ambr, including offline analytics, is analysed within the software to identify critical process parameters, optimise bioprocessing conditions, and define a robust design space for implementation in larger single-use BIOSTAT pilot and manufacturing scale bioreactors.
This extended DoE functionality is also available to existing ambr users who can assess the software via a free 60-day trial, with the option of purchasing the full version to continue running DoE programs.
First Automated Biospecimen Thawing System
BioCision, LLC's ThawSTAR™ automated sample thawing system is now available to address the “last mile” in the cryopreservation process. Utilizing patent-pending STAR™ sensing technology, the ThawSTAR system tailors the thaw cycle to the specific characteristics of each frozen sample. ThawSTAR technology integrates multiple detection algorithms to ensure uniform thermal profiles and reproducible recovery of frozen contents, eliminating the subjectivity found in conventional thaw methods.
The ThawSTAR sample thawing system is an intuitive, error-free method for achieving reproducible thawing and recovery results. Users simply insert a frozen vial and retrieve it when the vial is raised at the end of the thaw cycle. The automatic release of the vial, coupled with built-in audio and visual alarms, allow users to quickly retrieve thawed vials for downstream processing in order to minimize risk of toxicity from cryopreservatives, such as DMSO.

The ThawSTAR thawing system was engineered to deliver results similar to those achieved when thawing in a 37°C water bath, but with reproducibility and standardization built in. For more information, please visit biocision.com.
New Deals Announced for the Use of a Proprietary Vaccine Cell Line Platform
Valneva SE, a leading pure play vaccines biotech company, announced two new research license agreements for the development of veterinary vaccines using its EB66® vaccine cell line platform.

The first agreement allows Merial to evaluate the production of additional vaccine candidates using the EB66 cell line platform as a replacement for egg-based vaccine production. Valneva and Merial have been partnering for about ten years to generate EB66 cell-based veterinary vaccines. In May 2014, Merial received marketing approval by the European Medicines Agency (EMA) for its live EB66®-based Muscovy Duck Parvovirus Vaccine (MDPV), the first ever marketing authorization granted in Europe for a vaccine produced using the EB66 cell line.

Valneva also signed a new commercial license agreement with another European veterinary vaccine manufacturer to develop viral vaccines on its EB66 vaccine cell line platform. The license gives Valneva’s new partner the rights to conduct field trials with its selected vaccine candidates using the platform, and to commercialize the vaccines once they have received marketing approval.

To date, Valneva’s proprietary platform has enabled three veterinary vaccines and one human vaccine to be commercialized. For more information, please visit valneva.com.
Advertising
Economize by combining Techno-Blast and BioProcessing Journal advertising into one package.

Don't finalize your media plans for 2015 without consulting our media kit!
Email us to request a copy.
Career Development
Webinar:
Influenza Hemagglutination (HA) Quantification
March 25, 2015
2:00 PM EDT
ASGCT 18th Annual Meeting
May 13–16, 2015
New Orleans, Louisiana USA
BPJ Publishing






Update your profile and email address.
Or did a colleague forward this to you? Subscribe here.
While we'd hate to see you go, you can unsubscribe instantly.

[[tracking_beacon]]